83 related articles for article (PubMed ID: 27662800)
1. A new selective fluorescent probe based on tamoxifen.
Ho LA; Thomas E; McLaughlin RA; Flematti GR; Fuller RO
Bioorg Med Chem Lett; 2016 Oct; 26(20):4879-4883. PubMed ID: 27662800
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of fluorescent 4-hydroxytamoxifen conjugates with unique antiestrogenic properties.
Rickert EL; Oriana S; Hartman-Frey C; Long X; Webb TT; Nephew KP; Weatherman RV
Bioconjug Chem; 2010 May; 21(5):903-10. PubMed ID: 20420372
[TBL] [Abstract][Full Text] [Related]
3. Colocalization of Estrogen Receptors with the Fluorescent Tamoxifen Derivative, FLTX1, Analyzed by Confocal Microscopy.
Morales A; Marín R; Marrero-Alonso J; Boto A; Díaz M
Methods Mol Biol; 2016; 1366():163-173. PubMed ID: 26585134
[TBL] [Abstract][Full Text] [Related]
4. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
5. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
7. Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1.
Marrero-Alonso J; Morales A; García Marrero B; Boto A; Marín R; Cury D; Gómez T; Fernández-Pérez L; Lahoz F; Díaz M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):898-910. PubMed ID: 23727370
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
9. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
10. A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen receptor-independent mechanism of action in breast cancer cell lines.
Vessières A; Corbet C; Heldt JM; Lories N; Jouy N; Laïos I; Leclercq G; Jaouen G; Toillon RA
J Inorg Biochem; 2010 May; 104(5):503-11. PubMed ID: 20116857
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
Burke PJ; Koch TH
J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
13. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
14. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity.
Likhite VS; Stossi F; Kim K; Katzenellenbogen BS; Katzenellenbogen JA
Mol Endocrinol; 2006 Dec; 20(12):3120-32. PubMed ID: 16945990
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen.
Boyan BD; Sylvia VL; Frambach T; Lohmann CH; Dietl J; Dean DD; Schwartz Z
Endocrinology; 2003 May; 144(5):1812-24. PubMed ID: 12697687
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
Coezy E; Borgna JL; Rochefort H
Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
Oesterreich S; Zhang Q; Hopp T; Fuqua SA; Michaelis M; Zhao HH; Davie JR; Osborne CK; Lee AV
Mol Endocrinol; 2000 Mar; 14(3):369-81. PubMed ID: 10707955
[TBL] [Abstract][Full Text] [Related]
18. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in estrogen receptor-targeted probes conjugated to BODIPY dyes.
Gai L; Sun W
Steroids; 2022 Jul; 183():109031. PubMed ID: 35381270
[TBL] [Abstract][Full Text] [Related]
20. A molecular strategy to control tamoxifen resistant breast cancer.
Jiang SY; Jordan VC
Cancer Surv; 1992; 14():55-70. PubMed ID: 1423331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]